CEACAM5 and neoplasm: A biodistribution study was performed in humanised NSG mice after intravenous (i.v.)injection of either cibisatamab or CEACAM5-TCB in order to investigate the distribution of the two TCBs into the tumour interstitial space and their accumulation therein due to target binding.